Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients

Susan Keay, Eskild Petersen, Timothy Icenogle, Barry J. Zeluff, Tobias Samo, David Busch, Cheryl L Newman, William C. Bühles, Thomas C. Merigan

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CM V) infections in 22 heart and heart-lung transplant recipients at six medical centers was reviewed. All six heart-lung recipients and six of 16 heart recipients had CMV pneumonitis; five heart recipients had CMV gastrointestinal disease, three had retinitis, and two had infections in more than one organ system. Of the 18 patients (82%) surviving initial ganciclovir therapy, 16 improved, one stabilized, and one showed no change in clinical status. All cultures positive for CMV before treatment became negative during therapy. Six patients (33% of survivors) had recurrent episodes and received additional therapy. Four patients (18%) died during initial therapy; death was believed to be related to CMV infection in only two cases and to ganciclovir treatment in no case. Adverse reactions possibly attributable to ganciclovir included neutropenia (four patients), impaired renal function (one), thrombocytopenia (one), decreased blood pressure (one), and seizure (one). Ganciclovir appears to be well tolerated and to alter favorably the outcome of serious CMV infection in this patient population.

Original languageEnglish (US)
Pages (from-to)S563-S571
JournalReviews of Infectious Diseases
Volume10
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus Infections
Lung
Therapeutics
Infection
Retinitis
Gastrointestinal Diseases
Transplant Recipients
Neutropenia
Thrombocytopenia
Survivors
Pneumonia
Seizures
Blood Pressure
Kidney
Population

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. / Keay, Susan; Petersen, Eskild; Icenogle, Timothy; Zeluff, Barry J.; Samo, Tobias; Busch, David; Newman, Cheryl L; Bühles, William C.; Merigan, Thomas C.

In: Reviews of Infectious Diseases, Vol. 10, 01.01.1988, p. S563-S571.

Research output: Contribution to journalArticle

Keay, Susan ; Petersen, Eskild ; Icenogle, Timothy ; Zeluff, Barry J. ; Samo, Tobias ; Busch, David ; Newman, Cheryl L ; Bühles, William C. ; Merigan, Thomas C. / Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. In: Reviews of Infectious Diseases. 1988 ; Vol. 10. pp. S563-S571.
@article{ff595c34e20f4827bb45415b5cbad6cf,
title = "Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients",
abstract = "Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CM V) infections in 22 heart and heart-lung transplant recipients at six medical centers was reviewed. All six heart-lung recipients and six of 16 heart recipients had CMV pneumonitis; five heart recipients had CMV gastrointestinal disease, three had retinitis, and two had infections in more than one organ system. Of the 18 patients (82{\%}) surviving initial ganciclovir therapy, 16 improved, one stabilized, and one showed no change in clinical status. All cultures positive for CMV before treatment became negative during therapy. Six patients (33{\%} of survivors) had recurrent episodes and received additional therapy. Four patients (18{\%}) died during initial therapy; death was believed to be related to CMV infection in only two cases and to ganciclovir treatment in no case. Adverse reactions possibly attributable to ganciclovir included neutropenia (four patients), impaired renal function (one), thrombocytopenia (one), decreased blood pressure (one), and seizure (one). Ganciclovir appears to be well tolerated and to alter favorably the outcome of serious CMV infection in this patient population.",
author = "Susan Keay and Eskild Petersen and Timothy Icenogle and Zeluff, {Barry J.} and Tobias Samo and David Busch and Newman, {Cheryl L} and B{\"u}hles, {William C.} and Merigan, {Thomas C.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1093/clinids/10.Supplement_3.S563",
language = "English (US)",
volume = "10",
pages = "S563--S571",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients

AU - Keay, Susan

AU - Petersen, Eskild

AU - Icenogle, Timothy

AU - Zeluff, Barry J.

AU - Samo, Tobias

AU - Busch, David

AU - Newman, Cheryl L

AU - Bühles, William C.

AU - Merigan, Thomas C.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CM V) infections in 22 heart and heart-lung transplant recipients at six medical centers was reviewed. All six heart-lung recipients and six of 16 heart recipients had CMV pneumonitis; five heart recipients had CMV gastrointestinal disease, three had retinitis, and two had infections in more than one organ system. Of the 18 patients (82%) surviving initial ganciclovir therapy, 16 improved, one stabilized, and one showed no change in clinical status. All cultures positive for CMV before treatment became negative during therapy. Six patients (33% of survivors) had recurrent episodes and received additional therapy. Four patients (18%) died during initial therapy; death was believed to be related to CMV infection in only two cases and to ganciclovir treatment in no case. Adverse reactions possibly attributable to ganciclovir included neutropenia (four patients), impaired renal function (one), thrombocytopenia (one), decreased blood pressure (one), and seizure (one). Ganciclovir appears to be well tolerated and to alter favorably the outcome of serious CMV infection in this patient population.

AB - Experience with ganciclovir treatment of life-or sight-threatening cytomegalovirus (CM V) infections in 22 heart and heart-lung transplant recipients at six medical centers was reviewed. All six heart-lung recipients and six of 16 heart recipients had CMV pneumonitis; five heart recipients had CMV gastrointestinal disease, three had retinitis, and two had infections in more than one organ system. Of the 18 patients (82%) surviving initial ganciclovir therapy, 16 improved, one stabilized, and one showed no change in clinical status. All cultures positive for CMV before treatment became negative during therapy. Six patients (33% of survivors) had recurrent episodes and received additional therapy. Four patients (18%) died during initial therapy; death was believed to be related to CMV infection in only two cases and to ganciclovir treatment in no case. Adverse reactions possibly attributable to ganciclovir included neutropenia (four patients), impaired renal function (one), thrombocytopenia (one), decreased blood pressure (one), and seizure (one). Ganciclovir appears to be well tolerated and to alter favorably the outcome of serious CMV infection in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=0024040720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024040720&partnerID=8YFLogxK

U2 - 10.1093/clinids/10.Supplement_3.S563

DO - 10.1093/clinids/10.Supplement_3.S563

M3 - Article

C2 - 2847294

AN - SCOPUS:0024040720

VL - 10

SP - S563-S571

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -